2010 versus the 2000 consensus criteria in patients with normalised insulin‐like growth factor 1 after transsphenoidal surgery has high predictive values for long‐term recurrence‐free survival in acromegaly - Shen - 2021

The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. - Abstract - Europe PMC

Acromegaly - ScienceDirect

Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly - Careless - 2023 - Clinical Endocrinology - Wiley Online Library

Physiopathology, Diagnosis, and Treatment of GH Hypersecretion

Frontiers Development and Interpretation of Multiple Machine Learning Models for Predicting Postoperative Delayed Remission of Acromegaly Patients During Long-Term Follow-Up

Cells, Free Full-Text

Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma

Insulin-like growth factor-1 level is a poor diagnostic indicator of growth hormone deficiency

(PDF) How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review

Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance - Journal of Hepatology

pasireotide

Chapters Archive - Page 11 of 44 - Endotext

Assessment of sFRP4 as a bio-marker for predicting aggressiveness and recurrence of growth hormone-secreting pituitary adenomas